Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)

BACKGROUND: To compare survival outcomes of patients with advanced or metastatic non‐small cell lung cancer (NSCLC) who received immunotherapy as first‐, second‐ or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. METHODS: A retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz‐Patiño, Alejandro, Arrieta, Oscar, Cardona, Andrés F., Martín, Claudio, Raez, Luis E., Zatarain‐Barrón, Zyanya L., Barrón, Feliciano, Ricaurte, Luisa, Bravo‐Garzón, María A., Mas, Luis, Corrales, Luis, Rojas, Leonardo, Lupinacci, Lorena, Perazzo, Florencia, Bas, Carlos, Carranza, Omar, Puparelli, Carmen, Rizzo, Manglio, Ruiz, Rossana, Rolfo, Christian, Archila, Pilar, Rodríguez, July, Sotelo, Carolina, Vargas, Carlos, Carranza, Hernán, Otero, Jorge, Pino, Luis E., Ortíz, Carlos, Laguado, Paola, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996989/
https://www.ncbi.nlm.nih.gov/pubmed/31828967
http://dx.doi.org/10.1111/1759-7714.13272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996989/
https://www.ncbi.nlm.nih.gov/pubmed/31828967
http://dx.doi.org/10.1111/1759-7714.13272

Ejemplares similares